COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,580 Articles (22,415 medRxiv, 8,165 bioRxiv)

Most recent first Previous |  Page 483: Articles 4821-4830  | Next

Mental health self-care during the COVID-19 pandemic: a prospective cohort study in Australia
Griffiths, D., Pradipta, V. M. K. D., Collie, A.
10.1101/2022.12.08.22283265 — Posted: 2022-12-09
Atlas-scale single-cell multi-sample multi-condition data integration using scMerge2
Lin, Y., Cao, Y., Willie, E., Patrick, E., Yang, J. Y. H.
10.1101/2022.12.08.519588 — Posted: 2022-12-08
Effect of BNT162b2 antigen dosage on protection against SARS-CoV-2 omicron infection
Chemaitelly, H., Ayoub, H., Coyle, P. V., Tang, P., YASSINE, H. M., Althani, A., Al-Khatib, H. A., Hasan, M. R., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., Al-Romaihi, H. E., Butt, A. A., Al-Thani, M. H., Al-Khal, A., Bertollini, R., Abu-Raddad, L. J.
10.1101/2022.11.29.22282864 — Posted: 2022-12-08
Sample average treatment effect on the treated analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma
Mitra, A. K., Mukherjee, U. K., Mazumder, S., Madhira, V., Bergquist, T., Shao, Y. R., Liu, F., Song, Q., Su, J., Kumar, S., Bates, B. A., Sharafeldin, N., Topaloglu, U., on behalf of the National COVID Cohort Collaborative Consortium
10.1101/2022.12.07.22283208 — Posted: 2022-12-08
Mild SARS-CoV-2 infection results in long-lasting microbiota instability
Upadhyay, V., Suryawanshi, R., Tasoff, P., McCavitt-Malvido, M., Kumar, G. R., Murray, V., Noecker, C., Bisanz, J. E., Hswen, Y., Ha, C., Sreekumar, B., Chen, I. P., Lynch, S. V., Ott, M., Lee, S., Turnbaugh, P. J.
10.1101/2022.12.07.519508 — Posted: 2022-12-08
The Australian academic STEMM workplace post-COVID: a picture of disarray
Christian, K., Larkins, J.-a., Doran, M. R.
10.1101/2022.12.06.519378 — Posted: 2022-12-07
Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance.
O'Meara, T. R., Nanishi, E., McGrath, M. E., Barman, S., Dong, D., Dillen, C., Menon, M., Seo, H.-S., Dhe-Paganon, S., Ernst, R. K., Levy, O., Frieman, M. B., Dowling, D. J.
10.1101/2022.12.07.519460 — Posted: 2022-12-07
A Binary RNA and DNA Self-Amplifying Platform for Next Generation Vaccines and Therapeutics
Jefferies, W., Choi, K. B., Ribeca, P., Kari, S., Young, J., Hui, E., Qi, S. Y., Garrosvillas, E., Lincez, P., Welch, T., Saranchova, I., Pfeifer, C. G.
10.1101/2022.12.06.519322 — Posted: 2022-12-07
Serious harms of the COVID-19 vaccines: a systematic review
Gotzsche, P. C., Demasi, M.
10.1101/2022.12.06.22283145 — Posted: 2022-12-07
Causal Inference of CNS-regulated Hormones in COVID-19: A Bidirectional Two-sample Mendelian Randomization Study
Sun, Y., Ding, Z., Guo, Y., Yuan, J., Zhu, C., Pan, Y., Sun, R.
10.1101/2022.12.07.22283193 — Posted: 2022-12-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).